Ophthalmic Drugs Market Size to Grow US$ 68.93 Billion By 2030

The global ophthalmic drugs market size was approximate at US$ 37.35 billion in 2022 and is anticipated to grow US$ 68.93 billion by 2030, registering a compound annual growth rate of 7.96% from 2022 to 2030.

The ophthalmic drugs market report covering various industry elements and growth trends helpful for predicting the market’s future.

The study provides a strong base for the ophthalmic drugs market to be segmented into different segments. In fact, the study also covers the maximum market share during the assessment period by 2030.

This study is based on the partners that are highly competitive, key players as well as their market revenue in the forecast years of 2022 to 2030. There is also a strong focus on product revenues, sales, product categories and even the products that are experiencing the most traction. In this manner, the ophthalmic drugs report also speaks about the effectiveness of this market along with its growth during the forecast period of 2030. Other major attributes of the ophthalmic drugs market have been studied and analysed across many developments.

Request a Sample Copy of This Report @ https://www.precedenceresearch.com/sample/2441

Ophthalmic Drugs Market Report Scope 

Also read: Medical Equipment Rental Market Size to Grow US$ 90.66 Billion By 2030

Research Approach

The comprehensive report on the global ophthalmic drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products. Following this, the report provides detailed explanation of objectives of this study and laid down by accredited agencies in the purview of research in the global ophthalmic drugs market.

It is followed by market introduction, market dynamics, and an overview of the global market, which includes analysis of market drivers, restraints, and trends pertaining to the global market. Furthermore, Y-o-Y growth analysis with elaborated insights has been provided in order to understand the Y-o-Y growth trend of the global market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Key Players

• Johnson & Johnson services
• Novartis AG
• Bausch Health
• Santen pharmaceutical company limited
• Pfizer Inc.

Ophthalmic Drugs Market  Segmentations

By Disease

• Eye Allergy
• Eye Infection
• Glaucoma
• Retinal Disorders
• Dry Eye
• Others

By Drug Class

• Anti-Allergy
• Anti-Inflammatory
• Antiglaucoma
• Anti-VEGF Agents

By Dosage

• Eye Solutions
• Gels
• Capsules
• Eye Drops
• Ointments

By Administration

• Systematic
• Topical
• Local Ocular

By Product

• Prescription Drugs
• Over-the-Counter-Drugs

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Ophthalmic Drugs Market 

5.1. COVID-19 Landscape: Ophthalmic Drugs Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Ophthalmic Drugs Market, By Disease

8.1. Ophthalmic Drugs Market, by Disease, 2022-2030

8.1.1. Eye Allergy

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Eye Infection

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Glaucoma

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Retinal Disorders

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Dry Eye

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Ophthalmic Drugs Market, By Drug Class

9.1. Ophthalmic Drugs Market, by Drug Class, 2022-2030

9.1.1. Anti-Allergy

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Anti-Inflammatory

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Antiglaucoma

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Anti-VEGF Agents

9.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Ophthalmic Drugs Market, By Dosage 

10.1. Ophthalmic Drugs Market, by Dosage, 2022-2030

10.1.1. Eye Solutions

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Gels

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Dessert

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Eye Drops

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Ointments

10.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Ophthalmic Drugs Market, By Administration

11.1. Ophthalmic Drugs Market, by Administration, 2022-2030

11.1.1. Systematic

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Topical

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Local Ocular

11.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Ophthalmic Drugs Market, By Product

12.1. Ophthalmic Drugs Market, by Product, 2022-2030

12.1.1. Prescription Drugs

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Over-the-Counter-Drugs

12.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Ophthalmic Drugs Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Disease (2017-2030)

13.1.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.1.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.1.4. Market Revenue and Forecast, by Administration (2017-2030)

13.1.5. Market Revenue and Forecast, by Product (2017-2030)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Disease (2017-2030)

13.1.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.1.6.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.1.6.4. Market Revenue and Forecast, by Administration (2017-2030)

13.1.6.5. Market Revenue and Forecast, by Product (2017-2030)

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Disease (2017-2030)

13.1.7.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.1.7.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.1.7.4. Market Revenue and Forecast, by Administration (2017-2030)

13.1.7.5. Market Revenue and Forecast, by Product (2017-2030)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Disease (2017-2030)

13.2.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.2.4. Market Revenue and Forecast, by Administration (2017-2030)

13.2.5. Market Revenue and Forecast, by Product (2017-2030)

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Disease (2017-2030)

13.2.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2.6.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.2.7. Market Revenue and Forecast, by Administration (2017-2030)

13.2.8. Market Revenue and Forecast, by Product (2017-2030)

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Disease (2017-2030)

13.2.9.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2.9.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.2.10. Market Revenue and Forecast, by Administration (2017-2030)

13.2.11. Market Revenue and Forecast, by Product (2017-2030)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Disease (2017-2030)

13.2.12.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2.12.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.2.12.4. Market Revenue and Forecast, by Administration (2017-2030)

13.2.13. Market Revenue and Forecast, by Product (2017-2030)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Disease (2017-2030)

13.2.14.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2.14.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.2.14.4. Market Revenue and Forecast, by Administration (2017-2030)

13.2.15. Market Revenue and Forecast, by Product (2017-2030)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Disease (2017-2030)

13.3.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.3.4. Market Revenue and Forecast, by Administration (2017-2030)

13.3.5. Market Revenue and Forecast, by Product (2017-2030)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Disease (2017-2030)

13.3.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.6.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.3.6.4. Market Revenue and Forecast, by Administration (2017-2030)

13.3.7. Market Revenue and Forecast, by Product (2017-2030)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Disease (2017-2030)

13.3.8.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.8.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.3.8.4. Market Revenue and Forecast, by Administration (2017-2030)

13.3.9. Market Revenue and Forecast, by Product (2017-2030)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Disease (2017-2030)

13.3.10.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.10.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.3.10.4. Market Revenue and Forecast, by Administration (2017-2030)

13.3.10.5. Market Revenue and Forecast, by Product (2017-2030)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Disease (2017-2030)

13.3.11.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.11.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.3.11.4. Market Revenue and Forecast, by Administration (2017-2030)

13.3.11.5. Market Revenue and Forecast, by Product (2017-2030)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Disease (2017-2030)

13.4.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.4.4. Market Revenue and Forecast, by Administration (2017-2030)

13.4.5. Market Revenue and Forecast, by Product (2017-2030)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Disease (2017-2030)

13.4.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.6.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.4.6.4. Market Revenue and Forecast, by Administration (2017-2030)

13.4.7. Market Revenue and Forecast, by Product (2017-2030)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Disease (2017-2030)

13.4.8.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.8.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.4.8.4. Market Revenue and Forecast, by Administration (2017-2030)

13.4.9. Market Revenue and Forecast, by Product (2017-2030)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Disease (2017-2030)

13.4.10.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.10.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.4.10.4. Market Revenue and Forecast, by Administration (2017-2030)

13.4.10.5. Market Revenue and Forecast, by Product (2017-2030)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Disease (2017-2030)

13.4.11.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.11.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.4.11.4. Market Revenue and Forecast, by Administration (2017-2030)

13.4.11.5. Market Revenue and Forecast, by Product (2017-2030)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Disease (2017-2030)

13.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.5.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.5.4. Market Revenue and Forecast, by Administration (2017-2030)

13.5.5. Market Revenue and Forecast, by Product (2017-2030)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Disease (2017-2030)

13.5.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.5.6.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.5.6.4. Market Revenue and Forecast, by Administration (2017-2030)

13.5.7. Market Revenue and Forecast, by Product (2017-2030)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Disease (2017-2030)

13.5.8.2. Market Revenue and Forecast, by Drug Class (2017-2030)

13.5.8.3. Market Revenue and Forecast, by Dosage (2017-2030)

13.5.8.4. Market Revenue and Forecast, by Administration (2017-2030)

13.5.8.5. Market Revenue and Forecast, by Product (2017-2030)

Chapter 14. Company Profiles

14.1. Johnson & Johnson services

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Novartis AG

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Bausch Health

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Santen pharmaceutical company limited

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Pfizer Inc.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Why should you invest in this report?

If you are aiming to enter the global ophthalmic drugs market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for ophthalmic drugs are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com